Early Diffuse Scleroderma: Stem-Cell Transplant Against a Closing Eligibility Window
A single patient eight months into diffuse cutaneous systemic sclerosis, fourteen months from her first symptom, with early lung involvement. The disagreement isn't whether transplant works — it's whether waiting to find out costs her the chance to have it.
Dana R., a 43-year-old elementary school music teacher, first noticed her fingers turning white and painful at the piano keys fourteen months ago, and was diagnosed with diffuse cutaneous systemic sclerosis eight months ago, once the skin thickening spread past her wrists onto her forearms. She has otherwise been a healthy woman aside from Hashimoto's thyroiditis, well-controlled on levothyroxine for years before any of this began. Her modified Rodnan skin score, a hand-measured index of how much and how deeply the skin has thickened, has climbed from 14 to 28 over the past four months alone despite four months on mycophenolate mofetil at a reasonable dose — a rate of skin progression, not a static severity, that is itself the more worrying number.
Her most recent pulmonary function testing found her DLCO down to 68% of predicted from 82% six months earlier, and a chest HRCT now shows early, ground-glass interstitial changes that weren't there at diagnosis. That finding cuts two ways at once. It is exactly the kind of major-organ risk the SCOT trial's own high-risk enrollment criteria were built to catch early, before it becomes disabling — the trial randomized 75 patients with diffuse disease and lung or renal risk to myeloablative, CD34+-selected autologous transplant or twelve months of cyclophosphamide, and found 54-month event-free survival of 79% with transplant against 50% with cyclophosphamide (P=0.021), with DMARD initiation by 54 months down to 9% in the transplant arm against 44% on cyclophosphamide. But SCOT and its sister trial ASTIS also excluded patients whose pulmonary disease had already progressed past a defined severity — and her DLCO trend, while still early, is heading in exactly the direction that threshold exists to screen out. The question in front of the team isn't only whether transplant is the right call. It's whether continuing to treat her with an agent that has already failed to control her skin risks the decision closing on its own before anyone finishes making it.
At the referral visit, four months into a failing regimen
Her skin score has doubled on an adequately dosed mycophenolate trial, and the SCOT trial gives us real numbers for what happens if we wait: 54-month event-free survival of 79% with transplant against 50% with continued cyclophosphamide-based therapy, and DMARD initiation by 54 months in only 9% of the transplant arm against 44% who went on to need ongoing immunosuppression. I want her referred to a transplant center for formal eligibility evaluation now.
You're right that the 54-month numbers are real and hard to argue with on their own terms — I'm not disputing SCOT's result. But halving her skin score isn't the same as halving her risk. Treatment-related mortality in that same trial was 3%, and the transplant arm also carried more cytopenias and herpes zoster than the cyclophosphamide arm did.
Nine percent needing a DMARD by 54 months is a genuinely good outcome, but it doesn't offset an upfront, irreversible risk if a fuller trial of medical therapy — hers has run four months, short of the six to twelve most guidelines suggest before calling mycophenolate a real failure — still has room to work.
I'm not going to settle the transplant-versus-continue argument, because I don't think that's actually today's decision. SCOT and ASTIS both excluded patients whose pulmonary involvement had already progressed past a defined severity threshold, and her DLCO trend over six months — 82% down to 68%, with new ground-glass change on HRCT — is heading toward exactly that line.
If that trend continues for another six to twelve months, the option we're debating could simply no longer be available to her, regardless of which side of this argument turns out to be right. The actual decision today isn't transplant or not — it's referring her for eligibility evaluation now, in parallel with continuing and optimizing her medical therapy, so the choice doesn't quietly close on its own.
Agreed the same visit: refer to a transplant-experienced center for formal HSCT eligibility evaluation, continue and optimize mycophenolate mofetil in the interim, and repeat pulmonary function testing and echocardiography at a fixed interval specifically to catch any further movement toward the exclusion threshold before it's crossed.
Not agreed: whether, if she is confirmed eligible, the group should recommend proceeding to transplant once the workup clears, or first complete a fuller medical-therapy trial as long as the window allows. The rheumatologist would move to transplant once eligibility is confirmed regardless of mycophenolate's own trial length; the transplant physician wants the full medical-therapy trial exhausted first, for as long as her pulmonary trajectory permits it.